New combo therapy aims to stop limited cancer spread in its tracks
NCT ID NCT07481799
Summary
This study is testing whether combining a precise, high-dose radiation treatment (SBRT) with a new targeted drug (vibecotamab) can better control cancer that has spread to a few sites in the body. It is for adults with EGFR-positive solid tumors that have spread to 5 or fewer locations. The goal is to see if this combination can delay cancer growth and help patients live longer compared to standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGO-METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fifth Affiliated Hospital,Sun Yat-sen University
Zhuhai, Guangdong, 519099, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.